Business Wire

rf IDEAS celebrates 25 years of identity access management innovation.

30.4.2020 23:48:00 EEST | Business Wire | Press release

Share

As a leader in the identity access management industry, rf IDEAS welcomes its 25th year in business with a refreshed brand, revamped website, and new products in the WAVE ID® line of proximity and contactless identification, mobile credential and authentication readers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200430006013/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

WAVE ID® Nano USB-C (Photo: Business Wire)

A tradition of progressive product development and exceptional customer service is demonstrated in long-lasting partnerships with Imprivata, HP, and Google. "Collaboration is the key to our growth and leadership in the identity access management market," says David Cottingham, president of rf IDEAS. "Our new products—including great strides in contactless authentication—reflect our drive to create market solutions that anticipate and deliver on the changing needs of customers."

The redesigned rfIDEAS.com website guides customers to the ideal solution for applications such as employee identification, secure printing, time and attendance, and other areas, with biometric authentication solutions coming soon.

The company’s newest single sign-on solution, WAVE ID® Nano USB-C, delivers the same wireless reader technology now available in the fast-growing Type-C USB connector, in a design that stands up to hostile environments. It makes reader capabilities possible on smaller devices and is compatible with Apple, Google, and Microsoft USB-C enabled devices, clinician laptops, and mobility applications.

The company’s commitment to innovation and quality ensures that all processes, product quality control, development and overall corporate management meet and exceed customer expectations. As a result, rf IDEAS was listed for five consecutive years (2011 through 2015) on Inc. magazine's list of America's Fastest-Growing Private Companies prior to its acquisition in 2015 by Roper Technologies, Inc. New branding and product lines continue to reflect this dedication to thought leadership and innovation.

About rf IDEAS

rf IDEAS, Inc. is a leader in the card and credential reader space for healthcare, manufacturing, government, and enterprise. Partnering with leading technology companies, rf IDEAS readers enable innovative solutions for single sign-on, secure printing, attendance tracking, and other applications that require authentication. rf IDEAS readers support nearly all credential technologies worldwide and the growing set of mobile credentials. For more information, visit www.rfideas.com.

rf IDEAS® is a registered trademark of rf IDEAS, Inc. All other trademarks, service marks and product or service names are property of their respective owners

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
Arlene King
Marketing Manager
Ph: (866) 439-4884 Ext: 480
E: Marketing@RFIDeas.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 05:00:00 EEST | Press release

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and

Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 02:51:00 EEST | Press release

Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines, which includes biosimila

PMC Organometallix Announces Price Increase on All Products25.4.2026 00:02:00 EEST | Press release

Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli

Frankfurt Higher Regional Court upholds BESREMi ® arbitral award in favor of AOP Health24.4.2026 19:52:00 EEST | Press release

Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into

Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 17:37:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards. “We are honored and grateful to be selected for the CNPV which is a clear validation of both the urgent unmet need facing millions of people living with treatment resistant depression and the innovative science of COMP360,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “As the most advan

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye